NSGO-OV-UMB1; ENGOT-OV30 / NSGO: A Phase II Umbrella Trial in Patients With Relapsed Ovarian Cancer
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Oleclumab (Primary) ; Tavolimab (Primary) ; Tremelimumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms Umbrella Trial
- 06 Oct 2018 Planned End Date changed from 30 Sep 2022 to 30 Sep 2023.
- 06 Oct 2018 Planned primary completion date changed from 30 Mar 2019 to 30 Mar 2020.
- 01 Feb 2018 Status changed from not yet recruiting to recruiting.